Inspire Medical (INSP) — Buy the Selloff: High-Quality Cash Flow, Cheap Multiple, Clear Rebound Path

Hook & thesis

Inspire Medical (INSP) has been deeply marked down after guidance that narrowed revenue expectations earlier this year and a string of litigation headlines. That reaction looks overdone. The business is profitable, generates meaningful free cash flow, carries no recorded debt, and is trading at a single-digit P/E and a modest EV relative to cash flow. This is a trade idea to buy a fundamentally mispriced selloff: enter near $41.21, manage risk tightly, and target an outsized rebound as clarity returns to the Inspire V rollout and the market re-rates a cash-flow-positive med-tech name.

The plan is simple: build a position at $41.21, use a protective stop at $36.00 (below recent lows), and target $58.00 over a mid-term window. That target implies upside of roughly 40% from entry and brings valuation closer to a conservative growth multiple while still leaving room for upside if execution surprises to the upside.

Why the market should care - what Inspire does

Inspire Medical Systems develops and commercializes a minimally invasive implantable therapy for obstructive sleep apnea. The core product - Inspire therapy - combines a neurostimulator, stimulation lead, pressure-sensing lead, and a handheld remote. For patients who cannot tolerate CPAP, Inspire offers a non-CPAP option that has been adopted across the U.S. and other markets. Management has grown the installed base and monetization through procedure volume and device sales, and the business now produces both positive operating margins and free cash flow.

Fundamentals that support a buy-the-dip approach

• Profitability and cash flow: Reported earnings per share are about $4.55 and the stock trades around 9x earnings (P/E ~9.05). That is unusually low for a med-tech company with positive ROA (~14.4%) and ROE (~16.6%).
• Cash generation: Free cash flow in the most recent period was about $96.71M, a substantial number versus a market cap near $1.187B and enterprise value around $1.088B.
• Clean balance sheet: The company shows effectively no debt (debt-to-equity 0), and liquidity ratios (current ~6.34, quick ~4.48) point to a strong short-term position to weather temporary demand volatility.
• Valuation gap to history/highs: While the shares reached $147.03 in the 52-week period, today shares trade near $41.21 and at a P/S of ~1.3 and P/B of ~1.5, which implies the market is pricing in a permanent revenue impairment rather than a temporary slowdown tied to product rollout timing.

Support from the tape and technicals

Technically, the stock is near cycle lows: the 52-week low was $38.91 (06/03/2026) and current RSI sits around 38.8, indicating the name is not yet deeply oversold but has room to stabilize. Short interest has been elevated but manageable - recent settlement data show about 3.68M shares short (mid-May), representing low days-to-cover metrics (about 2.1 days on the most recent settlement), which sets up the potential for a quick squeeze if buyers step in following better-than-feared results or guidance clarity.

Valuation framing

At a market cap roughly $1.187B and an enterprise value near $1.088B, Inspire is cheap on several classic metrics for a profitable med-tech business: P/E ~9, EV/EBITDA ~16.1, EV/sales roughly 1.19, price-to-sales ~1.3, and price-to-book ~1.5. Put differently, the company’s free cash flow of ~$96.7M covers a meaningful portion of the market cap and creates a margin of safety that supports a tactical long. This is not a valuation that assumes no growth; instead, it prices in weak near-term growth or prolonged commercialization frictions. If Inspire stabilizes procedure growth and demonstrates better-than-feared uptake of the Inspire V or related upgrades, the multiple should re-rate toward med-tech norms.

Catalysts to watch (2-5)

• Incremental commercial traction and procedure growth - any signs that the Inspire V rollout is gaining traction with clinicians and payors will swing sentiment sharply.
• Quarterly financials and guidance clarity - a stable or modestly improved revenue guide on the next report would remove the principal overhang that drove the earlier selloff (05/05/2026 news linked to guidance narrowing).
• Reimbursement or payor wins - favorable coverage decisions materially improve the elective procedure cadence and backlog conversion.
• Reduced legal overhangs - progress or resolution in filed class actions (noting multiple filings in early 2026) would remove a headline risk and could deliver a multiple expansion.

Trade plan (actionable):

Entry: Buy at $41.21.
Stop loss: $36.00 (protective stop - below recent $38.91 low to avoid normal chop, limits downside).
Target: $58.00 (mid-term target that assumes a re-rating toward multiples consistent with stable cash flow and modest growth).
Horizon: Mid term (45 trading days). I expect the primary path to the target to run through improving clarity on guidance and commercial cadence over several weeks following the next earnings and/or company updates. This window gives time for procedure trends to show up in results and for sentiment to recover after headline-driven volatility.

Position sizing and execution notes

• Keep initial position moderate given ongoing headline risk: size to risk no more than 1-2% of portfolio capital to the stop at $36.00.
• Scale into strength: add into light-volume pullbacks above $40 and trim a portion if price reaches $50 to lock in gains and reduce single-event exposure.
• Use a hard stop; if the stop is hit, step back and reassess with new information rather than averaging down into a fundamental breakpoint.

Risks and counterarguments

• Execution risk on Inspire V rollout: The primary bearish case is that adoption ramps slower than management expects, leaving revenue below prior modeling. That’s exactly what triggered the earlier share decline and would keep valuation depressed.
• Legal overhangs: Multiple class action filings (early 2026) allege disclosure issues around product readiness and demand. Litigation could be protracted, costly, and distracting to management.
• Reimbursement and payor risk: If payors resist covering procedures or new device configurations, procedure volumes could fall below market expectations for longer than anticipated.
• Macroeconomic/Healthcare procedure risk: Elective procedure volumes are sensitive to consumer and hospital budgets; broader healthcare slowdown could pull procedure growth down across the category.

Counterargument to the long thesis: it is reasonable to argue that the market is correctly discounting a durable demand issue. If the Inspire V launch effects are structural - e.g., the device is harder to place, has lower clinician adoption, or payors systematically limit coverage - then profits and cash flow will compress and current valuation would still look optimistic. In that scenario, the stock could revisit lower levels and the stop at $36.00 would prevent larger losses.

What would change my mind

I would be less constructive if any of the following occur: (1) management provides guidance materially below even muted expectations at the next report; (2) adverse clinical data or device-related safety headlines emerge; (3) a court ruling creates a meaningful contingent liability; or (4) payors announce broad, unfavorable policy changes restricting coverage. Conversely, sustained procedure growth above management commentary, a clarified path to market for Inspire V, or evidence of improved payor coverage would strengthen the bullish case and likely push my target higher.

Bottom line

Inspire is a cash-generating med-tech company with a clean balance sheet, free cash flow near $97M, and a valuation that assumes prolonged weakness. That combination creates an attractive tactical long opportunity for disciplined traders: enter at $41.21, protect at $36.00, and aim for $58.00 over the next 45 trading days. The trade is not without headline risk, but the risk/reward is favorable given the company’s fundamentals and the path to re-rating if commercial momentum returns.

Quick snapshot table

Key execution checkpoints

• Next quarterly report and management commentary - confirm or refute the tightened guidance narrative.
• Procedure growth trends over the coming two to three quarters - look for sequential improvement.
• Any meaningful legal developments - settlements, dismissals, or rulings that reduce the litigation premium.

If you are an active trader who can handle headline volatility, this is a tactical, risk-defined opportunity: a cheap multiple, real cash flow, and a clear path to upside if operational clarity returns. The stop at $36 protects downside while the $58 target captures a conservative re-rating scenario. Stay nimble and reevaluate on each material update.